Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database

Cassier, P.A. et al. (2014) Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database. Annals of Oncology, 25(6), pp. 1222-1228. (doi: 10.1093/annonc/mdu108) (PMID:24608201)

Full text not currently available from Enlighten.


Background: Although sarcomas account for only 1% of all solid tumours, patients with sarcomas comprise a larger proportion of patients entering phase I trials, due to the limited number of registered or active drugs for these diseases. To help in patient selection, we evaluated the utility of the predictive Royal Marsden Score which had been derived in carcinoma patients. In addition, we analysed efficacy and toxicity regarding the sarcoma population enrolled in phase I trials. Patients and methods: We used data from a European Database comprising 2182 patients treated in phase I trials in 14 European institutions between 2005 and 2007. Results: One hundred and seventy-eight patients diagnosed with advanced sarcoma or other mesenchymal tumours were identified and accounted for 217 phase I trial participations during the study period. Histological type, class of drug, number of metastatic sites, high serum lactate dehydrogenase activity (LDH), low albumin and high white blood cell count were independent prognostic factors. Poor performance status (PS), liver metastases and high leucocyte count were associated with increased risk of early death. The class of drug used was the strongest predictor of progression-free survival (PFS) duration, inhibitors of angiogenesis and histone deacetylase giving the best results. Poor PS, high serum LDH and low lymphocyte count correlated with shorter PFS. In this heterogeneous population, PFS with investigational agents appeared comparable with that previously published for patients receiving standard treatments beyond first line. Conclusion: Prognostic factors in sarcoma patients do not differ from a broader phase I population. Efficacy measures suggest that some patients with sarcoma derive benefit from therapy in this setting which could therefore be considered for patients with no remaining standard therapeutic option.

Item Type:Articles
Additional Information:PAC was supported by a grant from the Fondation de France and the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC, French Federation of Cancer Centers): no. 2010, 12, 430—recherche clinique en cancérologie.
Glasgow Author(s) Enlighten ID:Evans, Professor Jeff
Authors: Cassier, P.A., Polivka, V., Judson, I., Soria, J.-C., Penel, N., Marsoni, S., Verweij, J., Schellens, J.H., Morales-Barrera, R., Schöffski, P., Voest, E.E., Gomez-Roca, C., Evans, T.R.J., Plummer, R., Gallerani, E., Kaye, S.B., and Olmos, D.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Annals of Oncology
ISSN (Online):1569-8041
Published Online:06 January 2020

University Staff: Request a correction | Enlighten Editors: Update this record